“bluebird-bio” Archives

in
Entry Author Date Location
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More 07/31/20 National
Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug 06/05/20 New York
BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info 05/13/20 New York
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More 04/03/20 National
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More 03/27/20 National
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
La Jolla Pharma’s Share Price Halves On Trial End, CEO Departure 11/26/19 San Diego
GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug 08/23/19 National
GlycoMimetics Sickle Cell Drug Flops as Others Creep Forward 08/05/19 New York
Mark Levin Named Xconomy’s 2019 Lifetime Achievement Award Winner in Boston 07/31/19 National
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease 06/14/19 Boston
Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More 06/07/19 National
Inhibrx, Fresh Off $40M Funding to Advance Cancer Drugs, Eyes IPO 06/03/19 San Diego
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval 06/03/19 Boston
Inhibrix Pulls In $40M to Press Ahead With Cancer Drug Clinical Trials 05/24/19 San Diego
ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups 05/13/19 Boston
Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More 05/10/19 National
Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round 04/22/19 San Diego
Panel Nod Moves Bluebird’s Gene Therapy Closer to Europe’s Market 03/29/19 Boston
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar 03/04/19 Boston
AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug 02/11/19 San Francisco
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy 01/31/19 New York
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B 01/03/19 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage 12/04/18 National
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
Page 1 of 7 next page »